SCHEMBL16629605

SCHEMBL16629605

c1ccc(-n2c3ccccc3c3ccc(-c4ccc5c6ccccc6n(-c6cccc7ccc8cccnc8c67)c5c4)cc32)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 3/20 0.36
CYP2C19 P33261 2/20 0.36
TSHR P16473 2/20 0.36
CYP3A4 P08684 2/20 0.36
GAA P10253 2/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
METAP2 P50579 1/20 0.35
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GMNN O75496 1/20 0.33
TP53 P04637 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629608 0.94 MAPT (0.41) KDM4EL3MBTL1MAPTNPSR1ALDH1A1
SCHEMBL16629603 0.93 KDM4E (0.40) KDM4EATML3MBTL1MAPTNPSR1
SCHEMBL16629628 0.91 KDM4E (0.42) KDM4EATML3MBTL1MAPTNPSR1
SCHEMBL16629630 0.91 KDM4E (0.42) KDM4EATML3MBTL1MAPTNPSR1
SCHEMBL16629604 0.87 GAA (0.39) KDM4EL3MBTL1MAPTNPSR1ALDH1A1
SCHEMBL16629629 0.86 KDM4E (0.41) KDM4EATML3MBTL1MAPTNPSR1
SCHEMBL16629622 0.86 METAP2 (0.39) KDM4EATML3MBTL1MAPTNPSR1
SCHEMBL16629644 0.86 CYP3A4 (0.45) KDM4EL3MBTL1MAPTNPSR1ALDH1A1
SCHEMBL16629636 0.85 GAA (0.40) KDM4EL3MBTL1MAPTNPSR1ALDH1A1
SCHEMBL17946129 0.84 KDM4E (0.40) KDM4EATML3MBTL1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices MERCK PATENT GMBH (DE) 2019-09-10 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2016-07-28 US disclosed
WO-2015049022-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160214942-A1 TRIARYLAMINE-SUBSTITUTED BENZO[H]QUINOLINE-DERIVATIVES AS MATERIALS FOR ELECTRONIC DEVICES KCNQ1, KCNH1, KCNQ2 KDM4E 1939/4885ATM 1799/4885L3MBTL1 2372/4885
US-10407394-B2 Triarylamine-substituted benzo[H]quinoline-derivatives as materials for electronic devices KCNQ1, KCNH1, KCNQ2 KDM4E 1939/4885ATM 1799/4885L3MBTL1 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.